CDKN2A and cancer: Interestingly, at the protein level, using IHC on the original patient sample, p16 expression and nuclear staining were limited to <1% of the cancer cells, with focal expression identified in some benign epithelial cells as well as stromal cells (Supplementary Fig. S2).